Literature DB >> 10900462

The proprotein convertases furin and PACE4 play a significant role in tumor progression.

D E Bassi1, H Mahloogi, A J Klein-Szanto.   

Abstract

Processing of latent precursor proteins by proprotein convertases (PCs) into their biologically active products is a common mechanism required for many important biologic functions. This process is tightly regulated, leading to the generation of active peptides and proteins including neuropeptides and polypeptide hormones, protein tyrosine phosphatases, growth factors and their receptors, and enzymes including matrix metalloproteases (MMPs). These processing reactions occurs at pairs of basic amino acids. Within the past several years, a novel family of Ca(2+)-dependent serine proteases has been identified, all of which possess homology to the endoproteases subtilisin (bacteria) and kexin (yeast). This family of PCs is currently comprised of fewer than a dozen members, known as furin/paired basic amino-acid-cleaving enzyme (PACE), PC1/PC3, PC2, PC4, PACE4, PC5/PC6, and PC7/PC8/lymphoma proprotein convertase. They share a high degree of amino-acid identity of 50-75% within their catalytic domains. Despite the relatively high degree of homology in the PC family, only PACE4 and furin localize to the same chromosome: mouse chromosome 7 and human chromosome 15. Recent reports have supported a possible functional role for PCs in tumorigenesis. For instance, convertases have been shown to be expressed in various tumor lines and human primary tumors. Furin and PACE4 process stromelysin 3 (MMP-11 or Str-3), an MMP involved in tumor invasion, into its mature, active form. Similarly, a growing family of MMPs, known as membrane-type metalloproteinases (MT-MMPs), and growth factors and adhesion molecules such as E-cadherin show similar amino-acid motifs and thus could be activated by furin and PACE4. These data, taken together with the high expression levels of PACE4 in 50% of murine chemically induced spindle cell tumors, confer to PACE4 and possibly other PCs a possible functional role in the activation of MMPs and consequently in tumor cell invasion and tumor progression. This was further supported by the remarkable enhancement in the invasive ability of the PACE4-transfected murine tumor cell lines. Mol. Carcinog. 28:63-69, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10900462

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  25 in total

1.  The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells.

Authors:  Vladimír Cermák; Jan Kosla; Jirí Plachý; Katerina Trejbalová; Jirí Hejnar; Michal Dvorák
Journal:  Cell Mol Life Sci       Date:  2010-05-28       Impact factor: 9.261

Review 2.  Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays.

Authors:  Bruno Ramos-Molina; Adam N Lick; Elias H Blanco; J Alejandro Posada-Salgado; Karina Martinez-Mayorga; Alan T Johnson; Guan-Sheng Jiao; Iris Lindberg
Journal:  Biochem Pharmacol       Date:  2015-05-21       Impact factor: 5.858

4.  Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6).

Authors:  Daniel E Bassi; Jonathan Cenna; Jirong Zhang; Edna Cukierman; Andres J Klein-Szanto
Journal:  Mol Carcinog       Date:  2014-05-21       Impact factor: 4.784

5.  Propeptides are sufficient to regulate organelle-specific pH-dependent activation of furin and proprotein convertase 1/3.

Authors:  Stephanie L Dillon; Danielle M Williamson; Johannes Elferich; David Radler; Rajendra Joshi; Gary Thomas; Ujwal Shinde
Journal:  J Mol Biol       Date:  2012-06-25       Impact factor: 5.469

6.  Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway.

Authors:  Meng Zhou; Youli Zhang; Hong Wei; Junbo He; Dawei Wang; Baoding Chen; Jian Zeng; Aihua Gong; Min Xu
Journal:  Oncol Lett       Date:  2017-12-20       Impact factor: 2.967

7.  Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

Authors:  Neil Senzer; Minal Barve; Joseph Kuhn; Anton Melnyk; Peter Beitsch; Martin Lazar; Samuel Lifshitz; Mitchell Magee; Jonathan Oh; Susan W Mill; Cynthia Bedell; Candice Higgs; Padmasini Kumar; Yang Yu; Fabienne Norvell; Connor Phalon; Nicolas Taquet; Donald D Rao; Zhaohui Wang; Chris M Jay; Beena O Pappen; Gladice Wallraven; F Charles Brunicardi; David M Shanahan; Phillip B Maples; John Nemunaitis
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

8.  Expression of paired basic amino acid-cleaving enzyme 4 (PACE4) correlated with prognosis in non-small cell lung cancer (NSCLC) patients.

Authors:  Yun-En Lin; Qi-Nian Wu; Xiao-Dong Lin; Guang-Qiu Li; Ya-Jie Zhang
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

Review 9.  Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy.

Authors:  Abdel-Majid Khatib; Géraldine Siegfried; Michel Chrétien; Peter Metrakos; Nabil G Seidah
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

10.  The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model.

Authors:  Xiaowei Sun; Rachid Essalmani; Nabil G Seidah; Annik Prat
Journal:  Mol Cancer       Date:  2009-09-08       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.